Pemvidutide
Pemvidutide (GLP-1 / glucagon dual agonist)
Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on preserving lean mass.
Overview
Pemvidutide is a GLP-1 and glucagon receptor dual agonist from Altimmune, developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The glucagon component adds energy expenditure and liver-fat reduction, and the program has emphasized preserving lean muscle mass during weight loss. It is investigational, with meaningful weight loss and liver improvement reported in trials. Update, September 2026: the IMPACT Phase 2b trial met its MASH-resolution endpoint at 24 weeks, and the Phase 3 PERFORMA trial in MASH began in August 2026.
Mechanism of action
Agonizes GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure and reduced liver fat.
Key studies & citations
- Human2025
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study
Once-weekly pemvidutide reduced liver fat content in MASLD, with the glucagon component acting directly on the liver.
Journal of Hepatology - Human2025
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a phase 2b study
Met MASH resolution without worsening of fibrosis at 24 weeks; did not meet fibrosis improvement at that timepoint.
The Lancet - Human2026
Altimmune announces second quarter 2026 financial results and business update
Phase 3 PERFORMA trial in MASH began in August 2026 with a 52-week readout expected in 2029; Breakthrough Therapy designation based on IMPACT 24-week data.
Altimmune press release (SEC 8-K exhibit)
Frequently asked questions
How does pemvidutide compare to survodutide?
Both are GLP-1/glucagon dual agonists targeting obesity and liver disease. They are separate investigational drugs from different companies.